Dr Ahmed brings more than 25 years of experience from the biopharmaceutical and CDMO industries. Most recently, he held a Managing Director position at QLife Pharma. Prior to this, he has held leadership positions at Dr. Reddy’s Laboratories, GSK-Stiefel, and Hoffmann-La Roche Inc. Ahmed has also served as a consultant for various biopharmaceutical companies on effective risk assessment (RA) control strategy, specification, and chemistry, manufacturing and control (CMC) modules, including CMC-Quality for various dosage forms development; investigational new drug, abbreviated new drug application, new drug application, 505b2, RA, and quality by design (QbD) filings; and both conventional and QbD-based tech-transfer across global sites.

Throughout his career, Dr Ahmed has served as a pharmaceutical product development and regulatory expert and has worked on a diverse portfolio of APIs and dosage forms. His in-depth experience extends to both small and large molecules (proteins and peptides), orals (tablets and capsules), controlled-modified release formulations, and parenteral dosages. He holds 21 patents on drug formulation and process in the United States and globally and has more than 30 presentations and publications of his work in various symposiums and conferences.

Dr Ahmed is a World Health Organization Fellow and member of a number of professional organizations. He holds a doctorate degree in pharmaceutical sciences from the University of Bath-England-UK and a bachelor’s degree in pharmacy from the University of Khartoum.